患者报告的抗逆转录病毒治疗依从性障碍:系统综述与Meta分析
该系统综述与Meta分析检索1997年1月1日至2016年3月31日MEDLINE、Embase、Web of Science和PsychINFO,纳入125项研究,覆盖17061名成人、1099名儿童和856名青少年,汇总各年龄组报告的抗逆转录病毒治疗依从性障碍比例。最常见个体障碍为忘记服药、离家在外和日常生活规律改变;抑郁在所有年龄组均被超过15%的患者报告为障碍。作者认为患者面临多重依从性障碍,单一干预不足以确保高依从性和持续病毒学抑制,卫生提供者应考虑分诊式方法。
要点
- 成人最常报告的依从性障碍为忘记服药(41.4%,95%CI 37.3%-45.4%)。
- 青少年忘记服药比例达63.1%(95%CI 46.3%-80.0%),高于成人和儿童/照护者。
- 抑郁在所有年龄组均被超过15%的患者报告为依从性障碍。
核心结论
- 接受抗逆转录病毒治疗的患者面临多重依从性障碍,单一干预不足以确保高依从性和持续病毒学抑制。
- 作者建议卫生提供者考虑分诊式方法,首先识别依从性差风险患者,再建立克服最重要依从性障碍所需的支持。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE via PubMed、Embase、Web of Science和PsychINFO,时间范围为1997年1月1日至2016年3月31日。
- 纳入125项报告抗逆转录病毒治疗依从性障碍的研究,数据覆盖17061名成人、1099名儿童和856名青少年。
- 按年龄组(成人、青少年、儿童)计算报告障碍的合并比例,并评估地理区域和经济发展水平的差异。
主要发现
- 忘记服药:成人41.4%(95%CI 37.3%-45.4%),青少年63.1%(95%CI 46.3%-80.0%),儿童/照护者29.2%(95%CI 20.1%-38.4%)。
- 离家在外:成人30.4%(95%CI 25.5%-35.2%),青少年40.7%(95%CI 25.7%-55.6%),儿童/照护者18.5%(95%CI 10.3%-26.8%)。
- 日常生活规律改变:成人28.0%(95%CI 20.9%-35.0%),青少年32.4%(95%CI 0%-75.0%),儿童/照护者26.3%(95%CI 15.3%-37.4%)。
- 抑郁:成人15.5%(95%CI 12.8%-18.3%),青少年25.7%(95%CI 17.7%-33.6%),儿童15.1%(95%CI 3.9%-26.3%);酒精/物质滥用:成人12.9%(95%CI 9.7%-16.1%),青少年28.8%(95%CI 11.8%-45.8%)。
- 保密/污名:成人13.6%(95%CI 11.9%-15.3%),儿童/照护者22.3%(95%CI 10.2%-34.5%);成人感觉生病15.9%(95%CI 13.0%-18.8%)较感觉良好9.3%(95%CI 7.2%-11.4%)更常被报告为障碍。
临床怎么用
- 作者认为,卫生提供者应考虑分诊式方法,首先识别依从性差风险患者,再建立克服最重要依从性障碍所需的支持。
局限性
- 纳入研究评估依从性障碍的方法不同,随访时长各异。
- 报告自我报告依从性的研究可能低估不依从的频率。
- 儿童障碍主要由照护者报告,可能不 correspond 于儿童面临的最重要障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintaining high levels of adherence to antiretroviral therapy (ART) is a challenge across settings and populations. Understanding the relative importance of different barriers to adherence will help inform the targeting of different interventions and future research priorities. METHODS AND FINDINGS: We searched MEDLINE via PubMed, Embase, Web of Science, and PsychINFO from 01 January 1997 to 31 March 2016 for studies reporting barriers to adherence to ART. We calculated pooled proportions of reported barriers to adherence per age group (adults, adolescents, and children). We included data from 125 studies that provided information about adherence barriers for 17,061 adults, 1,099 children, and 856 adolescents. We assessed differences according to geographical location and level of economic development. The most frequently reported individual barriers included forgetting (adults 41.4%, 95% CI 37.3%-45.4%; adolescents 63.1%, 95% CI 46.3%-80.0%; children/caregivers 29.2%, 95% CI 20.1%-38.4%), being away from home (adults 30.4%, 95% CI 25.5%-35.2%; adolescents 40.7%, 95% CI 25.7%-55.6%; children/caregivers 18.5%, 95% CI 10.3%-26.8%), and a change to daily routine (adults 28.0%, 95% CI 20.9%-35.0%; adolescents 32.4%, 95% CI 0%-75.0%; children/caregivers 26.3%, 95% CI 15.3%-37.4%). Depression was reported as a barrier to adherence by more than 15% of patients across all age categories (adults 15.5%, 95% CI 12.8%-18.3%; adolescents 25.7%, 95% CI 17.7%-33.6%; children 15.1%, 95% CI 3.9%-26.3%), while alcohol/substance misuse was commonly reported by adults (12.9%, 95% CI 9.7%-16.1%) and adolescents (28.8%, 95% CI 11.8%-45.8%). Secrecy/stigma was a commonly cited barrier to adherence, reported by more than 10% of adults and children across all regions (adults 13.6%, 95% CI 11.9%-15.3%; children/caregivers 22.3%, 95% CI 10.2%-34.5%). Among adults, feeling sick (15.9%, 95% CI 13.0%-18.8%) was a more commonly cited barrier to adherence than feeling well (9.3%, 95% CI 7.2%-11.4%). Health service-related barriers, including distance to clinic (adults 17.5%, 95% CI 13.0%-21.9%) and stock outs (adults 16.1%, 95% CI 11.7%-20.4%), were also frequently reported. Limitations of this review relate to the fact that included studies differed in approaches to assessing adherence barriers and included variable durations of follow up. Studies that report self-reported adherence will likely underestimate the frequency of non-adherence. For children, barriers were mainly reported by caregivers, which may not correspond to the most important barriers faced by children. CONCLUSIONS: Patients on ART face multiple barriers to adherence, and no single intervention will be sufficient to ensure that high levels of adherence to treatment and virological suppression are sustained. For maximum efficacy, health providers should consider a more triaged approach that first identifies patients at risk of poor adherence and then seeks to establish the support that is needed to overcome the most important barriers to adherence.
引用
- Shubber Z, Mills EJ, Nachega JB, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016. PMID: 27898679. doi:10.1371/journal.pmed.1002183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。